Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 6/20 | 0.55 |
| ▸ | DRD4 | P21917 | 6/20 | 0.55 |
| ▸ | DRD3 | P35462 | 6/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | NR5A1 | Q13285 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8778598 | 1.00 | DRD2 (0.55) | DRD2DRD4DRD3L3MBTL1KCNH2 | |
| SCHEMBL11428669 | 1.00 | DRD2 (0.55) | DRD2DRD4DRD3L3MBTL1KCNH2 | |
| SCHEMBL1044318 | 0.98 | DRD2 (0.57) | DRD2DRD4DRD3L3MBTL1KCNH2 | |
| SCHEMBL1047209 | 0.91 | DRD2 (0.59) | DRD2DRD4DRD3L3MBTL1KCNH2 | |
| SCHEMBL9011652 | 0.89 | DRD2 (0.65) | DRD2DRD4DRD3L3MBTL1KCNH2 | |
| SCHEMBL9011831 | 0.89 | DRD2 (0.65) | DRD2DRD4DRD3L3MBTL1KCNH2 | |
| SCHEMBL3805304 | 0.87 | DRD2 (0.68) | DRD2DRD4DRD3L3MBTL1KCNH2 | |
| SCHEMBL8458055 | 0.85 | NR5A1 (0.62) | GAANR5A1 | |
| SCHEMBL1047647 | 0.85 | DRD2 (0.55) | DRD2DRD4DRD3L3MBTL1KCNH2 | |
| SCHEMBL6748734 | 0.83 | MAPT (0.51) | DRD2DRD4DRD3L3MBTL1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150224099-A1 | ANTITUBERCULOUS COMPOSITION COMPRISING OXAZOLE COMPOUNDS | OTSUKA PHARMA CO LTD (JP) | 2015-08-13 | — | — | US | disclosed |
| CN-102532162-B | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMA CO LTD | 2015-05-27 | — | — | CN | disclosed |
| US-8987304-B2 | Antituberculous composition comprising oxazole compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2015-03-24 | — | — | US | disclosed |
| CN-101522657-B | STAT3/5 activation inhibitor | OTSUKA PHARMACEUTICAL CO.,LTD. (JP) | 2014-10-15 | — | — | CN | disclosed |
| EP-1957073-B1 | MEDICINAL DRUG | OTSUKA PHARMA CO LTD (JP) | 2014-04-23 | — | — | EP | disclosed |
| EP-2612858-A1 | STAT3/5 activation inhibitor | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-07-10 | — | — | EP | disclosed |
| CN-1993339-B | Aromatic compound | OTSUKA PHARMA CO LTD | 2013-05-22 | — | — | CN | disclosed |
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| CN-102895230-A | Antituberculous composition comprising oxazole compounds | OTSUKA PHARMA CO LTD | 2013-01-30 | — | — | CN | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| CN-1993339-A | Aromatic compound | OTSUKA PHARMA CO LTD (JP) | 2007-07-04 | — | — | CN | disclosed |
| WO-2007066784-A2 | DIARYLETHER DERIVATIVES AS ANTITUMOR AGENTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-06-14 | — | — | WO | disclosed |
| WO-2007043542-A1 | ANTITUBERCULOUS COMPOSITION COMPRISING OXAZOLE COMPOUNDS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-04-19 | — | — | WO | disclosed |
| EP-1773797-A2 | AROMATIC COMPOUNDS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-04-18 | — | — | EP | disclosed |
| CN-1878777-A | 2,3-dihydro-6-nitroimidazo (2,1-b) oxazole compounds for the treatment of tuberculosis | OTSUKA PHARMA CO LTD (JP) | 2006-12-13 | — | — | CN | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| WO-2006014012-A2 | AROMATIC COMPOUNDS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-02-09 | — | — | WO | disclosed |
| CN-1705670-A | 2, 3-dihydro-6-nitroimidazo [2, 1-b ] oxazole compounds | OTSUKA PHARMA CO LTD (JP) | 2005-12-07 | — | — | CN | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150224099-A1 | ANTITUBERCULOUS COMPOSITION COMPRISING OXAZOLE COMPOUNDS | OXA1L, ARG1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | DRD2 2614/4885DRD4 888/4885DRD3 1127/4885 |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | DRD2 542/4885DRD4 368/4885DRD3 132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.